Inhibition of platelet aggregation by a new agent, Ticlopidine.
Effect of Ticlopidine, 5-(2-chlorobenzyl)-4, 5, 6, 7-tetrahydro[3,2-C]pyridine hydro-chloride, on platelet aggregation was studied in the rat. Ticlopidine was found to be a potent, long-lasting inhibitor of platelet aggregation. It inhibited the aggregation induced by any of ADP, collagen, thrombin, arachidonic acid and prostaglandin endoperoxides and/or thromboxane A2-like substancee. Ticlopidine was effective at doses as low as 30 mg/kg when orally given to rats, and the effect lasted as long as the life span of the circulating platelets (half time: about 48 hours). Ticlopidine inhibited also nucleotide release from and prostaglandin synthesis in the platelets, but did not significantly affect platelet adhesiveness to glass, platelet factor 3 availability and clot retraction.
D000244:Adenosine Diphosphate / Q000494:pharmacology; D000818:Animals; D001095:Arachidonic Acids / Q000494:pharmacology; D001792:Blood Platelets / Q000502:physiology; D002470:Cell Survival; D003094:Collagen / Q000494:pharmacology; D008297:Male; D010974:Platelet Aggregation / Q000187:drug effects*; D011462:Prostaglandins G / Q000494:pharmacology; D011725:Pyridines / Q000494:pharmacology*; D051381:Rats; D013876:Thiophenes / Q000494:pharmacology*; D013917:Thrombin / Q000494:pharmacology; D013928:Thromboxane A2 / Q000494:pharmacology
D001095:Arachidonic Acids; D011462:Prostaglandins G; D011725:Pyridines; D013876:Thiophenes; D013928:Thromboxane A2; D000244:Adenosine Diphosphate; D003094:Collagen; D013917:Thrombin